LORRAIN DANIEL S. (Chief Scientific Officer) sold 2.5% of their position (4.17K shares) of CONTINEUM THERAPEUTICS, INC. on the open market
Open‑market sale worth $43.5K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 1/6/2026ACC: 0001437749-26-000616
Officer· Chief Scientific Officer
Since Mar 2026
-4.17K
Net shares
Net seller
$43.5K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
4.17K disposed
Non-Derivative Transactions2
Class A Common Stock
Direct
Shares
−3.67K
Price / share
$10.35
Trade value
$37.98K
% of position
2.2%
1/5/2026
164.39K→160.72K
Class A Common Stock
Direct
Shares
−500.00
Price / share
$11.13
Trade value
$5.56K
% of position
0.3%
1/5/2026
160.72K→160.22K
Total
Net shares
−4.17K
Net value
-$43.54K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 1/5/2026 | S · Sale | −3.67K | $10.35 | $37.98K | 2.2% | 164.39K | 160.72K |
| Class A Common Stock Direct | 1/5/2026 | S · Sale | −500.00 | $11.13 | $5.56K | 0.3% | 160.72K | 160.22K |
| Total | −4.17K | -$43.54K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Class A Common Stock
IndirectShares owned6.84K
Total
6.84K indirect6.84K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Common Stock | 6.84K | Indirect |
| Total | 6.84K | 6.84K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported